Want Dividends to Pay Your Medicare Premiums? Here’s How Much You Need
Medicare Part B premiums keep climbing, and Social Security checks keep shrinking to cover them. Three Dividend Kings with very different yields and coverage profiles could shift that math entirely in a retiree's favor.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
For anyone on Medicare, the Part B premium is a bill that arrives every month without fail, usually withheld right out of the Social Security check. CMS set the standard monthly Part B premium at $202.90 for 2026, an increase of $17.90 from $185.00 in 2025. The question this article answers is simple: what does it take, in capital, for dividends alone to cover that recurring line item? Three blue-chip Dividend Kings, PepsiCo (NASDAQ:PEP | PEP Price Prediction), Johnson & Johnson (NYSE:JNJ), and Coca-Cola (NYSE:KO), offer three different combinations of yield, coverage, and dividend track record to do exactly that.
There are a couple caveats to this roster. First, the annual Part B deductible is $283 in 2026, an increase of $26 from $257 in 2025, so the premium is not the only Part B cash outflow. Second, income-related monthly adjustment amounts affect roughly 8% of people with Medicare Part B, and higher-income filers pay meaningfully more, all the way up to $689.90 per month at the top bracket. The math below is anchored to the standard premium.
PepsiCo: The Highest Yield in the Trio
PepsiCo trades at $137.63 with a dividend yield of 4.06%, the richest starting yield in this bundle. The current quarterly payout is $1.48 per share, with an annualized forward dividend of $5.92 per share. For an income investor trying to defray Medicare, PEP delivers the most premium coverage per dollar of capital in this group.
Free cash flow yield of 4.08% essentially matches the dividend yield, and management guides FY2026 total cash returns of about $8.9B, with dividends around $7.9B, funded by free cash flow conversion of at least 80%. Interest coverage sits at 12.03x. The dividend track record is the anchor: PepsiCo announced a 4% annualized dividend increase beginning with the June 2026 payment, representing the 54th consecutive annual increase, comfortably a Dividend King.
The bull case for a Medicare-focused income investor is that PEP offers a rare combination of a 4%-plus yield on a wide-moat consumer staple with more than five decades of payout growth, backed by international momentum (LatAm Foods +15%, EMEA +10%, Asia Pacific Foods +12% in Q2 2026). The caveat is that PFNA revenue declined about 2% in Q2 on weaker effective net pricing and core operating margin contracted 40 basis points, while the balance sheet carries a debt/equity ratio of 2.45. Coverage is fine; margin discipline is the thing to watch.
Johnson & Johnson: The Longest Streak, the Deepest Coverage
Johnson & Johnson trades at $275.23, with a market cap near $663.3B. The current quarterly payout is $1.34, with an annualized forward dividend of $5.36 per share. JNJ has the lowest headline yield of the three but arguably the strongest cash-flow cushion, and the longest streak.
The board approved a 3.1% dividend increase in Q1 2026 to $1.34 per share quarterly, marking the 64th consecutive year of dividend increases. Coverage is not close: FY2025 free cash flow was $19.7B against a dividend load that JNJ can absorb many times over. FY2026 guidance was raised to reported sales of $100.3B to $101.3B and adjusted EPS of $11.45 to $11.65, and Q1 2026 revenue landed at $24.06B, up 9.9% year over year. Standout oncology assets include DARZALEX at $3.96B (+22.5%) and CARVYKTI at $597M (+62.1%).
The bull case for retirees is straightforward: 64 years of consecutive increases, a diversified pharma and MedTech portfolio, and a planned Orthopaedics separation that sharpens focus. The caveat is STELARA biosimilar erosion of 59.7% in Q1, creating roughly a 920 basis point drag on Innovative Medicine growth, alongside ongoing litigation charges of $330M in Q1 2026 and $854M in Q4 2025. Neither dents dividend coverage, but both drag headline earnings comparisons.
Coca-Cola: Iconic Payer, Richest Valuation
Coca-Cola trades at $88.07 with a dividend yield of 2.32%. The current quarterly payout is $0.53 per share, with an annualized forward dividend of $2.12 per share. That yield is the lowest of the three, which means KO requires the most capital to fund the same Medicare bill. What KO offers in exchange is best-in-class quality metrics and one of the most durable payout histories in the entire market.
The dividend record supplied shows sustained annual increases from $0.16 per share in 1999 through $0.53 per share in 2026, consistent with KO’s status as a widely recognized Dividend King with more than 60 years of consecutive annual increases. Coverage is comfortable: FY2026 guidance calls for organic revenue growth of about 5%, comparable EPS growth of 9% to 10%, and free cash flow of roughly $12.4B. Return on equity runs 45.97%, with a gross margin of 61.6% and operating margin of 28.7%. Q2 2026 delivered revenue of $13.38B (+6.7% YoY) with global unit case volume up 5%, led by India, China, US, and Brazil.
The bull case is quality plus staying power: a wide-moat brand system, high-return operations, and FIFA World Cup 2026 activation driving volumes. The caveat is valuation. KO trades at a P/E of roughly 29 and a P/FCF of roughly 72, which caps the effective yield an investor gets on new capital and leaves less margin for error if consumer demand softens.
Blending the Three Kings
Three Dividend Kings, three different tradeoffs against one recurring bill. PEP’s 4.06% yield does the heaviest lifting per dollar of capital, JNJ pairs a lower yield with $19.7B in annual free cash flow and a 64-year streak, and KO trades the thinnest current yield for arguably the most bulletproof brand economics in staples. Split evenly, the blend gives a Medicare-focused retiree a coverage profile that does not depend on any single company holding its price, its payout, or its end market (if you want a wider bench of 50-plus-year raisers screened by valuation, we ranked ten of them in a free Dividend Kings report). And because the 2026 Part B standard premium of $202.90 was a $17.90 increase from 2025, dividend growth, not just dividend yield, is what keeps this strategy intact as premiums drift higher.
Contact [email protected] for any questions or corrections.
Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.
